Cellular Human Tissue-engineered Skin Substitute - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511248608

Publication Date:

November 22, 2024

Pages:

140

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Cellular Human Tissue-engineered Skin Substitute was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Cellular Human Tissue-engineered Skin Substitute was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cellular Human Tissue-engineered Skin Substitute was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Cellular Human Tissue-engineered Skin Substitute was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Cellular Human Tissue-engineered Skin Substitute include Allergan (AbbVie), AlloSource, Organogenesis, BD, Smith & Nephew, Integra LifeSciences, Synthes (Johnson & Johnson), Axogen and Vericel Corporation, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cellular Human Tissue-engineered Skin Substitute, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cellular Human Tissue-engineered Skin Substitute by region & country, by Type, and by Application.
The Cellular Human Tissue-engineered Skin Substitute market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cellular Human Tissue-engineered Skin Substitute.
麻豆原创 Segmentation
By Company
Allergan (AbbVie)
AlloSource
Organogenesis
BD
Smith & Nephew
Integra LifeSciences
Synthes (Johnson & Johnson)
Axogen
Vericel Corporation
LifeNet Health
MTF Biologics
Arthrex
Wright Medical Group NV (Stryker)
Cook Biotech Incorporated
Aroa Biosurgery
Surgalign Holdings
Segment by Type:
Cellular Allogeneic
Cellular Autologous
Others
Segment by Application
Hospitals
Specialty Clinics
Wound Care Centers
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cellular Human Tissue-engineered Skin Substitute manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Cellular Human Tissue-engineered Skin Substitute in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Cellular Human Tissue-engineered Skin Substitute in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Cellular Human Tissue-engineered Skin Substitute Product Introduction
1.2 Global Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Size Forecast
1.2.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Value (2019-2030)
1.2.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume (2019-2030)
1.2.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Price (2019-2030)
1.3 Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Trends & Drivers
1.3.1 Cellular Human Tissue-engineered Skin Substitute Industry Trends
1.3.2 Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Drivers & Opportunity
1.3.3 Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Challenges
1.3.4 Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cellular Human Tissue-engineered Skin Substitute Players Revenue Ranking (2023)
2.2 Global Cellular Human Tissue-engineered Skin Substitute Revenue by Company (2019-2024)
2.3 Global Cellular Human Tissue-engineered Skin Substitute Players Sales Volume Ranking (2023)
2.4 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Company Players (2019-2024)
2.5 Global Cellular Human Tissue-engineered Skin Substitute Average Price by Company (2019-2024)
2.6 Key Manufacturers Cellular Human Tissue-engineered Skin Substitute Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Cellular Human Tissue-engineered Skin Substitute Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Cellular Human Tissue-engineered Skin Substitute
2.9 Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Competitive Analysis
2.9.1 Cellular Human Tissue-engineered Skin Substitute 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Cellular Human Tissue-engineered Skin Substitute Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cellular Human Tissue-engineered Skin Substitute as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cellular Allogeneic
3.1.2 Cellular Autologous
3.1.3 Others
3.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Type
3.2.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Value, by Type (2019-2030)
3.2.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Value, by Type (%) (2019-2030)
3.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Type
3.3.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume, by Type (2019-2030)
3.3.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume, by Type (%) (2019-2030)
3.4 Global Cellular Human Tissue-engineered Skin Substitute Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.1.3 Wound Care Centers
4.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Application
4.2.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Value, by Application (2019-2030)
4.2.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Value, by Application (%) (2019-2030)
4.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Application
4.3.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume, by Application (2019-2030)
4.3.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume, by Application (%) (2019-2030)
4.4 Global Cellular Human Tissue-engineered Skin Substitute Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Region
5.1.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Region (2019-2024)
5.1.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Region (2025-2030)
5.1.4 Global Cellular Human Tissue-engineered Skin Substitute Sales Value by Region (%), (2019-2030)
5.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Region
5.2.1 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Region (2019-2024)
5.2.3 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Region (2025-2030)
5.2.4 Global Cellular Human Tissue-engineered Skin Substitute Sales Volume by Region (%), (2019-2030)
5.3 Global Cellular Human Tissue-engineered Skin Substitute Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
5.4.2 North America Cellular Human Tissue-engineered Skin Substitute Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
5.5.2 Europe Cellular Human Tissue-engineered Skin Substitute Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
5.6.2 Asia Pacific Cellular Human Tissue-engineered Skin Substitute Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
5.7.2 South America Cellular Human Tissue-engineered Skin Substitute Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
5.8.2 Middle East & Africa Cellular Human Tissue-engineered Skin Substitute Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cellular Human Tissue-engineered Skin Substitute Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cellular Human Tissue-engineered Skin Substitute Sales Value
6.2.1 Key Countries/Regions Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
6.2.2 Key Countries/Regions Cellular Human Tissue-engineered Skin Substitute Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
6.3.2 United States Cellular Human Tissue-engineered Skin Substitute Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cellular Human Tissue-engineered Skin Substitute Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
6.4.2 Europe Cellular Human Tissue-engineered Skin Substitute Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cellular Human Tissue-engineered Skin Substitute Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
6.5.2 China Cellular Human Tissue-engineered Skin Substitute Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cellular Human Tissue-engineered Skin Substitute Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
6.6.2 Japan Cellular Human Tissue-engineered Skin Substitute Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cellular Human Tissue-engineered Skin Substitute Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
6.7.2 South Korea Cellular Human Tissue-engineered Skin Substitute Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cellular Human Tissue-engineered Skin Substitute Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
6.8.2 Southeast Asia Cellular Human Tissue-engineered Skin Substitute Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cellular Human Tissue-engineered Skin Substitute Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cellular Human Tissue-engineered Skin Substitute Sales Value, 2019-2030
6.9.2 India Cellular Human Tissue-engineered Skin Substitute Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cellular Human Tissue-engineered Skin Substitute Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Allergan (AbbVie)
7.1.1 Allergan (AbbVie) Company Information
7.1.2 Allergan (AbbVie) Introduction and Business Overview
7.1.3 Allergan (AbbVie) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Allergan (AbbVie) Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.1.5 Allergan (AbbVie) Recent Development
7.2 AlloSource
7.2.1 AlloSource Company Information
7.2.2 AlloSource Introduction and Business Overview
7.2.3 AlloSource Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.2.4 AlloSource Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.2.5 AlloSource Recent Development
7.3 Organogenesis
7.3.1 Organogenesis Company Information
7.3.2 Organogenesis Introduction and Business Overview
7.3.3 Organogenesis Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Organogenesis Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.3.5 Organogenesis Recent Development
7.4 BD
7.4.1 BD Company Information
7.4.2 BD Introduction and Business Overview
7.4.3 BD Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.4.4 BD Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.4.5 BD Recent Development
7.5 Smith & Nephew
7.5.1 Smith & Nephew Company Information
7.5.2 Smith & Nephew Introduction and Business Overview
7.5.3 Smith & Nephew Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Smith & Nephew Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.5.5 Smith & Nephew Recent Development
7.6 Integra LifeSciences
7.6.1 Integra LifeSciences Company Information
7.6.2 Integra LifeSciences Introduction and Business Overview
7.6.3 Integra LifeSciences Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Integra LifeSciences Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.6.5 Integra LifeSciences Recent Development
7.7 Synthes (Johnson & Johnson)
7.7.1 Synthes (Johnson & Johnson) Company Information
7.7.2 Synthes (Johnson & Johnson) Introduction and Business Overview
7.7.3 Synthes (Johnson & Johnson) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Synthes (Johnson & Johnson) Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.7.5 Synthes (Johnson & Johnson) Recent Development
7.8 Axogen
7.8.1 Axogen Company Information
7.8.2 Axogen Introduction and Business Overview
7.8.3 Axogen Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Axogen Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.8.5 Axogen Recent Development
7.9 Vericel Corporation
7.9.1 Vericel Corporation Company Information
7.9.2 Vericel Corporation Introduction and Business Overview
7.9.3 Vericel Corporation Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Vericel Corporation Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.9.5 Vericel Corporation Recent Development
7.10 LifeNet Health
7.10.1 LifeNet Health Company Information
7.10.2 LifeNet Health Introduction and Business Overview
7.10.3 LifeNet Health Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.10.4 LifeNet Health Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.10.5 LifeNet Health Recent Development
7.11 MTF Biologics
7.11.1 MTF Biologics Company Information
7.11.2 MTF Biologics Introduction and Business Overview
7.11.3 MTF Biologics Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.11.4 MTF Biologics Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.11.5 MTF Biologics Recent Development
7.12 Arthrex
7.12.1 Arthrex Company Information
7.12.2 Arthrex Introduction and Business Overview
7.12.3 Arthrex Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Arthrex Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.12.5 Arthrex Recent Development
7.13 Wright Medical Group NV (Stryker)
7.13.1 Wright Medical Group NV (Stryker) Company Information
7.13.2 Wright Medical Group NV (Stryker) Introduction and Business Overview
7.13.3 Wright Medical Group NV (Stryker) Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Wright Medical Group NV (Stryker) Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.13.5 Wright Medical Group NV (Stryker) Recent Development
7.14 Cook Biotech Incorporated
7.14.1 Cook Biotech Incorporated Company Information
7.14.2 Cook Biotech Incorporated Introduction and Business Overview
7.14.3 Cook Biotech Incorporated Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Cook Biotech Incorporated Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.14.5 Cook Biotech Incorporated Recent Development
7.15 Aroa Biosurgery
7.15.1 Aroa Biosurgery Company Information
7.15.2 Aroa Biosurgery Introduction and Business Overview
7.15.3 Aroa Biosurgery Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Aroa Biosurgery Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.15.5 Aroa Biosurgery Recent Development
7.16 Surgalign Holdings
7.16.1 Surgalign Holdings Company Information
7.16.2 Surgalign Holdings Introduction and Business Overview
7.16.3 Surgalign Holdings Cellular Human Tissue-engineered Skin Substitute Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Surgalign Holdings Cellular Human Tissue-engineered Skin Substitute Product Offerings
7.16.5 Surgalign Holdings Recent Development
8 Industry Chain Analysis
8.1 Cellular Human Tissue-engineered Skin Substitute Industrial Chain
8.2 Cellular Human Tissue-engineered Skin Substitute Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cellular Human Tissue-engineered Skin Substitute Sales Model
8.5.2 Sales Channel
8.5.3 Cellular Human Tissue-engineered Skin Substitute Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Allergan (AbbVie)
AlloSource
Organogenesis
BD
Smith & Nephew
Integra LifeSciences
Synthes (Johnson & Johnson)
Axogen
Vericel Corporation
LifeNet Health
MTF Biologics
Arthrex
Wright Medical Group NV (Stryker)
Cook Biotech Incorporated
Aroa Biosurgery
Surgalign Holdings

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.